Literature DB >> 16956450

Amiodarone: a multifaceted antiarrhythmic drug.

Bramah N Singh1.   

Abstract

Synthesized as an antianginal compound 40 years ago, amiodarone has emerged as a uniquely effective antiarrhythmic compound in recent years. It has numerous properties, the most prominent being the ability to lengthen repolarization in the atria and ventricles associated with bradycardia without the significant potential for torsades de pointes. Amiodarone effectively controls a wide spectrum of atrial and ventricular antiarrhythmic disorders, but its limiting side effects, such as thyroid dysfunction, pulmonary fibrosis, and dermatologic changes, may limit its long-term use in some patients. What aspects of the multiplicity of the properties of amiodarone are relevant to its unusual efficacy is not known. Deiodination and other structural changes in the amiodarone molecule have has led to a the loss of thyroid and pulmonary effects in the resulting derivative, dronedarone, which is in advanced clinical development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956450     DOI: 10.1007/s11886-006-0074-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

1.  Rise and Fall of Guided Antiarrhythmic Therapy for Ventricular Tachycardia and Fibrillation.

Authors: 
Journal:  J Cardiovasc Pharmacol Ther       Date:  1996-04       Impact factor: 2.457

2.  Amiodarone and Homogeneity of Ventricular Repolarization and Refractoriness.

Authors: 
Journal:  J Cardiovasc Pharmacol Ther       Date:  1996-10       Impact factor: 2.457

Review 3.  Low-dose amiodarone for atrial fibrillation: time for a prospective study?

Authors:  H R Middlekauff; I Wiener; L A Saxon; W G Stevenson
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

4.  Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone.

Authors:  W Sun; J S Sarma; B N Singh
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

5.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.

Authors: 
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

Review 6.  Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.

Authors:  B N Singh
Journal:  Am J Cardiol       Date:  1996-08-29       Impact factor: 2.778

7.  Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Authors:  Stuart J Connolly; Paul Dorian; Robin S Roberts; Michael Gent; Steven Bailin; Eric S Fain; Kevin Thorpe; Jean Champagne; Mario Talajic; Benoit Coutu; Gerian C Gronefeld; Stefan H Hohnloser
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

8.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

Review 9.  Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.

Authors:  Bramah N Singh; Nitin Wadhani
Journal:  J Cardiovasc Pharmacol Ther       Date:  2004-09       Impact factor: 2.457

10.  The effect of amiodarone, a new anti-anginal drug, on cardiac muscle.

Authors:  B N Singh; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

View more
  13 in total

Review 1.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

2.  Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Future Cardiol       Date:  2011-11

Review 3.  [Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].

Authors:  C Pott; D G Dechering; A Muszynski; S Zellerhoff; A Bittner; K Wasmer; G Mönnig; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-12

4.  Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent.

Authors:  Zhi-fang Yang; Ci-zhen Li; Wei Wang; Ying-min Chen; Ying Zhang; Yuan-mou Liu; Hong-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-01-24       Impact factor: 6.150

5.  Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Luiz Belardinelli; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

6.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

7.  Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Electrofisiol Arritm       Date:  2010-10

8.  Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; José M Di Diego; Serge Sicouri; Marcela Ferreiro; Leif Carlsson; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-09-16       Impact factor: 6.343

Review 9.  Atrial-selective sodium channel block for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

10.  A predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues.

Authors:  Celinda M Kofron; Tae Yun Kim; Bum-Rak Choi; Kareen L K Coulombe; Fabiola Munarin; Arvin H Soepriatna; Rajeev J Kant; Ulrike Mende
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.